$8.87
-0.98-9.95%
Last update: Nov 10, 5:14 PM
Capricor Therapeutics Inc
CAPRNASDAQ
Capricor Therapeutics rose 77.2% from $5.56 to $9.85, ahead of the S&P 500's +10.0%. Its worst day was Jul 27 (−64.5%), and its low came Jul 31 at $3.85.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.54 beat the $-0.54 estimate on $0.00 revenue (est. $1.2M).
+11.5% · S&P 500 +0.2%
Capricor Therapeutics shares rose 460.0%, while the S&P 500 rose 0.1%.
Story events cover the past 12 months · Times ET
+460.0%, the year's best day · S&P 500 +0.1%
EPS of $-0.62 missed the $-0.53 estimate on $0.00 revenue (est. $1.7M).
−8.7% · S&P 500 −0.6%
Capricor Therapeutics closed at its highest level of the year, 535.6% above where the year started.
+3.3% · S&P 500 −0.7%
EPS of $-0.59 missed the $-0.54 estimate on $0.00 revenue (est. $25.2M).
−3.8% · S&P 500 +0.6%
Capricor Therapeutics closed at its lowest level of the year, 30.8% below where the year started.
−8.1% · S&P 500 +0.7%
EPS of $-0.70 missed the $-0.58 estimate on $0.00 revenue.
+58.0%, on 66M shares, the year's heaviest volume · S&P 500 −0.2%
Where it ended: a close of $9.85 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.45, revenue est. $10.4M).
Nothing in the past 12 months.
All CAPR dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CAPR and SPY from Benzinga historical bars. Not investment advice.
